San Diego-based startup Gallant is taking a confident step into the future of veterinary care. With a fresh injection of $18 million in funding, the company is set to launch the first FDA-approved ready-to-use stem cell therapy for pets, aiming to address common health issues using a novel approach.
Initially, Gallant is targeting Feline Chronic Gingivostomatitis (FCGS), a painful oral condition in cats. Early indications are promising: dogs treated for arthritis have shown improved mobility and less pain, with benefits holding for up to two years. While treatments for feline kidney disease have produced mixed outcomes, Gallant is already planning the next phase of research to tackle this challenge.
What sets Gallant apart is its streamlined use of ready-to-use cells from donor animals—even if they come from a different species. This method simplifies the treatment process, eliminating the need for cells harvested directly from the patient or closely matched donors. It’s a fresh and practical twist on stem cell therapy, traditionally associated with human medicine.
The venture has naturally drawn in keen investors. The latest round was led by Digitalis Ventures, with NovaQuest Capital Management also stepping in. Given NovaQuest’s track record—including backing the first FDA-approved human stem cell therapy—there’s a sense of strong belief in Gallant’s potential.
Gallant’s story is as compelling as its science. Founded by Aaron Hirschhorn, who previously sold DogVacay to Rover, the company has found new momentum under the leadership of Linda Black, its president and chief scientific officer. With over $44 million raised to date, Gallant is positioning itself as a transformative player in pet healthcare.
